PRTA$8.67
$9.15
Chart
Performance
Key Stats
AI PRTA Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralProthena Corporation plc shows potential in its specific niche within biotechnology, particularly with its pipeline targeting neurodegenerative diseases. However, its current financial performance, high cash burn, and lack of profitability, coupled with mixed technical indicators, result in a neutral overall assessment. Investors should monitor clinical trial progress and strategic partnerships closely.
Thematic
Prothena operates within the growing field of protein dysregulation therapies, with a focus on significant unmet needs in neurodegenerative diseases like Parkinson's and Alzheimer's. The company's pipeline addresses major healthcare trends, but its success is heavily reliant on clinical trial outcomes.
Fundamental
Prothena exhibits a weak fundamental profile due to significant cash burn, negative earnings, and no current revenue from marketed products. While it has substantial cash reserves to fund operations, profitability remains a distant prospect.
Technical
Technical indicators for Prothena are mixed. While the stock has shown some resilience and is trading above longer-term moving averages, short-term indicators suggest caution due to a bearish MACD and RSI in oversold territory on shorter timeframes.
| Factor | Score |
|---|---|
| Neurodegenerative Disease Therapies | 85 |
| Biotechnology Innovation | 80 |
| Clinical Trial Progress | 70 |
| Partnerships & Collaborations | 80 |
| Regulatory Landscape | 60 |
| Factor | Score |
|---|---|
| Valuation | 10 |
| Profitability | 5 |
| Growth | 70 |
| Balance Sheet Health | 70 |
| Cash Flow | 10 |
| Factor | Score |
|---|---|
| Trend Analysis | 60 |
| Momentum | 50 |
| Volume Confirmation | 40 |
| Support & Resistance | 50 |
| MACD | 40 |
AI Investing Checklist
Powered by LiveAIBullish Points (6)
Positive Revenue Growth Momentum
The company has shown a positive revenue growth trend, with revenue increasing from $53.91M in 2022 to $135.16M in 2024.
Strong Cash Position
The company has a substantial cash position, with cash and cash equivalents of $471.39M as of Q4 2024.
Bearish Points (9)
Consistent Net Losses
The company has reported net losses in the trailing twelve months (-$177.15M) and for the fiscal years 2022, 2023, and 2024, indicating ongoing profitability challenges.
Negative P/E Ratio
The Price-to-Earnings (P/E) ratio is negative (-1.9 TTM, -6.1 for 2024), which is not uncommon for companies in the development stage but indicates no current earnings to base valuation on.
Calendar
August 2025
8
Next Earnings Date
H: $-1.33
A: $-1.79
L: $-2.57
H: 37.50M
A: 6.18M
0Profile
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
Seasonals
Price Target
24.29 USD
The 39 analysts offering 1 year price forecasts for PRTA have a max estimate of 81.00 and a min estimate of 4.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 100
Strategic partner for Prothena's PRX004 program targeting ATTR amyloidosis, a key pipeline asset.
Weight: 98
Strategic partner for Prothena's prasinezumab program targeting Parkinson's disease (alpha-synuclein), a significant neurodegenerative focus.
Weight: 95
Leading competitor in ATTR amyloidosis with approved RNAi therapies (Onpattro, Amvuttra), directly competing with Prothena's ATTR amyloidosis programs.
Weight: 93
Major competitor in ATTR amyloidosis with tafamidis (Vyndaqel/Vyndamax), a leading oral therapy, directly competing with Prothena's ATTR amyloidosis programs.